Cabralealactone exhibits antimycobacterial activity against Mycobacterium tuberculosis and demonstrates moderate cytotoxicity against the NCI-H187 small-cell lung cancer cell line, with weaker effects on a breast cancer line. This natural product is a candidate for research in infectious disease and oncology, suitable for in vitro mechanistic studies.